Image based quantitation of molecular translocation

Information

  • Patent Grant
  • 8150136
  • Patent Number
    8,150,136
  • Date Filed
    Wednesday, March 16, 2005
    19 years ago
  • Date Issued
    Tuesday, April 3, 2012
    12 years ago
Abstract
The use of an imaging system, cell compartment markers, and molecular markers in methods for correlating the movement of molecules within a cell to a particular compartment are provided, including measuring and correlating molecule movement in adherent and non-adherent cells.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present disclosure relates generally to methods for detecting specific molecules in cells, and more specifically, to the use of imagery in methods for quantitating the movement of molecules within a cell, including adherent and non-adherent cells, such as movement to the nucleus, or to another cellular organelle or compartment.


2. Description of the Related Art


Signal transduction pathways regulate most cellular biological processes and have a critical influence on cellular responses to external stimuli. Typically, cell surface receptors that bind to a specific extracellular mediator trigger a cascade of intracellular signaling events that alter cellular metabolism or gene expression, and such changes contribute to the cellular response. The intracellular signaling cascade often involves the translocation of transcription factors or second messengers from the cytoplasm to the nucleus.


Historically, nuclear translocation events have been studied microscopically by observing the sub-cellular localization of fluorescent probe-labeled signaling molecules. Until recently, microscopic applications have been limited due to the subjective nature and the lack of means to quantitate imagery. Currently, several quantitative plate based microscopy platforms are available that attempt to quantitate translocation (ArrayScan, Cellomics, Inc. (Pittsburgh, Pa.); Laser Scanning Cytometer, Compucyte Corporation (Cambridge, Mass.); IN Cell Analyzer, Amersham International plc. (Little Chalfont, England)). However, these microscopy platforms typically rely on the use of adherent cell lines, and their biological responses may differ from suspension-type cells (which include most blood cells).


Traditionally, the measurement of the translocation of fluorescently bound molecules into the nucleus has been determined by a method referred to as the Nuc-Cyt difference (Ding et al., J. Biol. Chem. 273:28897, 1998). This measurement involves the following steps: (1) determining the boundaries of the nucleus which has been stained with a nuclear stain; (2) eroding the mask or area contained with in the boundaries to insure the entire area is within the nucleus; (3) summing up the total fluorescence intensity associated from the labeled molecules of interest (Total Nuclear Fluorescence); (4) dilating the nuclear boundary to determine an annular ring solely contained in the cytoplasm and integrate the fluorescence associated with the labeled molecule of interest (Annular Cytoplasm Fluorescence); and (5) calculating the difference between the Total Nuclear and Annular Cytoplasm Fluorescence to yield the Nuc-Cyt difference. However, this method is unlikely to produce the best measurement because it relies on an accurate nuclear mask, subjective erosion and dilation routines that determine the nuclear and cytoplasmic boundaries, an additional subjective dilation of the cytoplasm mask to create an annular volume, and both the cytoplasm and the nucleus have areas that are not represented in the calculation.


Thus, the need exists for techniques that can allow quantitation of molecular transport, such as nuclear translocation, in cells in flow to afford the opportunity to study suspension-based cell lines as well as primary cells. For example, such techniques would allow detailed analysis of nuclear translocation responses in subset of cells, such as blood cells. The present invention meets such needs, and further provides other related advantage.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows staining of NFκB nuclear translocation in A-549 cells using immunofluorescence microscopy.



FIGS. 2A and 2B show staining of NFκB nuclear translocation in A-549 cells using multispectral imaging.



FIG. 2C shows staining of nuclear translocation of NF-κB in immune cells. The left panel shows a monocytic cell line imaged simultaneously in darkfield, green fluorescence (fluorescein isothiocyanate (FITC) labeled anti-NF-κB), brightfield, and red fluorescence (nuclear stain 7-aminoactinomycin D). Each image row represents a different, single cell. The first cell is untreated and cells 2-4 have been treated with lipopolysaccharide (LPS). The right panel is a statistical analysis of the imagery that quantitatively characterizes the degree of NF-κB translocation to the nucleus.



FIG. 3 shows quantitation of NFκB nuclear translocation in A-549 cells using image correlation analysis (see FIG. 3 for more detail).



FIG. 4 shows staining of NFκB nuclear translocation in THP-1 cells using immunofluorescence microscopy.



FIG. 5 shows staining and quantitation of NFκB nuclear translocation in THP-1 cells using multispectral imaging. Untreated (a) and LPS treated (b) THP-1 cells were prepared as described in FIG. 4 and imaged in flow using the ImageStream 100 platform. Plotting NF-κB/7-AAD Similarity vs. NF-κB Peak Intensity revealed a range of cells based on similarity that were gated into three populations. Each gated population has an associated image gallery that can be visually inspected. The image galleries here display the NF-κB image adjacent to a composite image (green NF-κB/red 7-ADD) for each object within a given population. Morphologic inspection of the image galleries revealed that NF-κB had translocated to the nucleus in ‘High Similarity’ but not ‘Low Similarity’ cells. ‘Medium Similarity’ cells had a diffuse NF-κB staining pattern. Untranslocated and translocated cells had significantly different Similarity values (untreated: −1.36 +/−0.84 and 2.98 +/−0.35, respectively; LPS treated: −0.76 +/−0.64 and 3.35 +/−0.48, respectively). Treatment with LPS significantly increased the percentage of NF-κB-translocated (0.71%, median similarity value 2.98 +/−0.35 to 44.6%, median similarity value 3.35 +/−0.48) and Medium Similarity (3.6% to 27.6%) cells.



FIG. 6 shows nuclear translocation of NF-κB in THP-1 cells (monocyte cell line) untreated (from left, first panel, images; second panel, quantitation of first panel images) and treated with LPS (third panel, images; fourth panel, quantitation of third panel images). Images are from darkfield, NF-κB labeled, brightfield, and 7-AAD nuclear labeled.



FIG. 7 shows images of nuclear translocation of NF-κB in THP-1 cells untreated (left panel) and treated with LPS (right panel). Images include brightfield and a composite of cells stained with anti-NF-κB and with 7-AAD.



FIG. 8 shows 7-AAD mask and NF-κB mask used in a compartmental correlation feature calculation.



FIG. 9 shows quantitation of compartmental correlation feature in untreated and LPS-treated THP-1 cells.



FIGS. 10A and 10B show imagery of THP-1 cells (A) untreated and (B) LPS-treated, and the three populations (untranslocated—green, transitional—yellow, and translocated—red) identified in the quantitation of FIG. 9.



FIG. 11 shows images of nuclear translocation of NF-KB in adherent A-549 cells untreated (from left, first panel, images; second panel, quantitation of first panel images) and treated with IL-1β/TNF-α (third panel, images; fourth panel, quantitation of third panel images). Images are from darkfield, NF-κB labeled, brightfield, and 7-AAD nuclear labeled.



FIG. 12 shows images of nuclear translocation of NF-κB in A-549 cells untreated (left panel) and treated with IL-1β/TNF-α (right panel). Images include brightfield and a composite of cells stained with anti-NF-κB and with 7-AAD.



FIG. 13 shows quantitation of compartmental correlation feature in untreated and IL-1β/TNF-α-treated A-549 cells.





DETAILED DESCRIPTION

The instant disclosure relates to the use of multi-mode imagery of cells, including in non-adherent and adherent cell types, to monitor or identify molecular processes and movement in and between all cellular compartments. An advantage of the methods provided in the instant disclosure is that the shortcomings of the Nuc-Cyt difference calculation discussed above are generally obviated. Specifically, the methods of the instant disclosure use a measurement based upon statistical correlation, referred to herein as Compartmental Correlation Feature (CCF), which is a more robust method than the Nuc-Cyt calculation because (i) a single Nuclear Mask is used, (ii) spatial information is taken into account, (iii) subjective dilation, erosion, and annular dilation routines are not required, and (iv) the entire cellular nucleus is taken into account. Discussed in more detail below are single-step methods of using morphometric and photometric features from comprehensive multispectral imagery, in combination with CCF, to permit the analysis or observation of, for example, molecular movement or transport into a cell, out of a cell, within a cell, or between subcellular compartments. Thus, it should be understood that reference herein to “movement of a molecule in a cell” encompasses movement or transport of a molecule or molecules into a cell, out of a cell, within a cell, or between subcellular compartments, and combinations thereof. An exemplary image system for use with the methods in the instant disclosure is an ImageStream® 100 multispectral imaging flow cytometer platform, which produces high-resolution brightfield, darkfield, and fluorescence images with the simplified sample handling and quantitative power of flow cytometry. In addition, the IDEAS™ analysis software can quantify over 200 photometric and morphometric parameters for each cell that passes through the imaging system, including parameters that can quantify the cellular and sub-cellular location of molecules, probes, and other indigenous or exogenous compounds within a cell.


In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer, etc.), unless otherwise indicated. As used herein, the term “about” means ±15%. As used herein, the use of an indefinite article, such as “a” or “an”, should be understood to refer to the singular and the plural of a noun or noun phrase (i.e., meaning “one or more” of the enumerated elements or components). The use of the alternative (e.g., “or”) should be understood to mean either one, both or any combination thereof of the alternatives.


By way of background, methodologies for simultaneous high speed multispectral imaging in brightfield, darkfield, and four channels of fluorescence of cells in flow were recently developed (see, e.g., U.S. Pat. Nos. 6,211,955 and 6,249,341). U.S. Patent Application No. 2002/0146734 illustrates an exemplary imaging system (e.g., the ImageStream platform). Cells are hydrodynamically focused into a core stream and orthogonally illuminated for both darkfield and fluorescence imaging. The cells are simultaneously trans-illuminated via a spectrally-limited source (e.g., filtered white light or a light emitting diode) for brightfield imaging. Light is collected from the cells with an imaging objective lens and is projected on a charge-coupled detector (CCD). The optical system has a numeric aperture of 0.75 and the CCD pixel size in object space is 0.5 microns square, allowing high resolution imaging at event rates of approximately 100 cells per second. Each pixel is digitized with 10 bits of intensity resolution, providing a minimum dynamic range of three decades per pixel. In practice, the spread of signals over multiple pixels results in an effective dynamic range that typically exceeds four decades per image. Additionally, the sensitivity of the CCD can be independently controlled for each multispectral image, resulting in a total of approximately six decades of dynamic range across all the images associated with an object.


Prior to projection on the CCD, the light is passed through a spectral decomposition optical system that directs different spectral bands to different lateral positions across the detector (see, e.g., U.S. Pat. No. 6,249,341). With this technique, an image is optically decomposed into a set of 6 sub-images, each corresponding to a different color component and spatially isolated from the remaining sub-images. This process allows for identification and quantitation of signals within the cell by physically separating on the detector signals that may originate from overlapping regions of the cell. Spectral decomposition also allows multimode imaging: the simultaneous detection of brightfield, darkfield, and multiple colors of fluorescence. This is exemplified in the figures of U.S. Patent Application No. 2002/0146734, which depicts a red brightfield illumination source and the associated transmitted light images in the red detector channel adjacent to fluorescent and scattered light images in the other spectral channels. The process of spectral decomposition occurs during the image formation process rather than via digital image processing of a conventional composite image.


The CCD may be operated using a technique called time-delay-integration (TDI), a specialized detector readout mode that preserves sensitivity and image quality even with fast relative movement between the detector and the objects being imaged. As with any CCD, image photons are converted to photocharges in an array of pixels. However, in TDI operation the photocharges are continuously shifted from pixel to pixel down the detector, parallel to the axis of flow. If the photocharge shift rate is synchronized with the velocity of the flowing cell's image, the effect is similar to physically panning a camera: image streaking is avoided despite signal integration times that are orders of magnitude longer than in conventional flow cytometry. For example, an instrument may operate at a continuous data rate of approximately 30 megapixels per second and integrate signals from each object for 10 milliseconds, allowing the detection of even faint fluorescent probes within cell images that are acquired at high-speed. Careful attention to pump and fluidic system design to achieve highly laminar, non-pulsatile flow eliminates any cell rotation or lateral translation on the time scale of the imaging process (see, e.g., U.S. Pat. No. 6, 532,061).


A real-time algorithm analyzes every pixel read from the CCD to detect the presence of object images and calculate a number of basic morphometric and photometric features, which can be used as criteria for data storage. Data files encompassing 10,000-20,000 cells are typically about 100 MB in size and, therefore, can be stored and analyzed using standard personal computers. The TDI readout process operates continuously without any “dead time”, which means every cell can be imaged and the coincidental imaging of two or more cells at a time presents no barrier to data acquisition.


Such an imaging system can be employed to determine morphological, photometric, and spectral characteristics of cells and other objects by measuring optical signals, including light scatter, reflection, absorption, fluorescence, phosphorescence, luminescence, etc.


As used herein, “morphological parameters” may be basic (e.g., nuclear shape) or may be complex (e.g., identifying cytoplasm size as the difference between cell size and nuclear size). For example, morphological parameters may include nuclear area, perimeter, texture or spatial frequency content, centroid position, shape (i.e., round, elliptical, barbell-shaped, etc.), volume, and ratios of any of these parameters. Morphological parameters may also include cytoplasm size, texture or spatial frequency content, volume and the like, of cells. Morphological parameters may also be of other organelles (e.g., mitochondria) or for other cellular compartments (e.g., plasma membrane or organelle membrane).


As used herein, “photometric measurements” with the aforementioned imaging system can enable the determination of nuclear optical density, cytoplasm optical density, background optical density, and the ratios of any of these values. An object being imaged can be stimulated into fluorescence or phosphorescence to emit light, or may be luminescent wherein light is produced without stimulation. In each case, the light from the object may be imaged on a TDI detector of the imaging system to determine the presence and amplitude of the emitted light, the number of discrete positions in a cell or other object from which the light signal(s) originate(s), the relative placement of the signal sources, and the color (wavelength or waveband) of the light emitted at each position in the object.


In using an imaging system as described herein, it should be made clear that a separate light source is not required to produce an image of the object (cell), if the object is luminescent (i.e., if the object produces light). However, many of the applications of an imaging system as described herein will require that one or more light sources be used to provide light that is incident on the object being imaged. A person having ordinary skill in the art will know that the location of the light sources substantially affects the interaction of the incident light with the object and the kind of information that can be obtained from the images on a TDI detector.


In addition to imaging an object with the light that is incident on it, a light source can also be used to stimulate emission of light from the object. For example, a cell having been contacted with probe conjugated to a fluorochrome (e.g., such as FITC, PE, APC, Cy5, or Cy5.5) will fluoresce when excited by light, producing a corresponding characteristic emission spectra from any excited fluorochrome probe that can be imaged on a TDI detector. Light sources may alternatively be used for causing the excitation of fluorochrome probes on an object, enabling a TDI detector to image fluorescent spots produced by the probes on the TDI detector at different locations as a result of the spectral dispersion of the light from the object that is provided by prism. The disposition of these fluorescent spots on the TDI detector surface will depend upon their emission spectra and their location in the object.


Each light source may produce light, which can either be coherent, non-coherent, broadband or narrowband light, depending upon the application of the imaging system desired. Thus, a tungsten filament light source can be used for applications in which a narrowband light source is not required. For applications such as stimulating the emission of fluorescence from probes, narrowband laser light is preferred, since it also enables a spectrally decomposed, non-distorted image of the object to be produced from light scattered by the object. This scattered light image will be separately resolved from the fluorescent spots produced on a TDI detector, so long as the emission spectra of any of the spots are at different wavelengths than the wavelength of the laser light. The light source can be either of the continuous wave (CW) or pulsed type, preferably a pulsed laser. If a pulsed type illumination source is employed, the extended integration period associated with TDI detection can allow the integration of signal from multiple pulses. Furthermore, it is not necessary for the light to. be pulsed in synchronization with the TDI detector.


The present disclosure provides methods of using both photometric and morphometric features derived from multi-mode imagery of objects in flow. Such methods can be employed to analyze molecular movement within or between cells, in heterogeneous populations of cells when entrained in a fluid flowing through an imaging system. As used herein, cells may be eukaryotic or prokaryotic or viral, human, non-human animal, plant, unicellular, a primary cell culture or culture-adapted cell line, immortalized or immortalizable, differentiated or differentiatable, and the like. In addition, cells may be genetically engineered (transduced, transformed or transfected) with one or more chromosomally integrated or episomal recombinant nucleic acid sequences. The cells may have been exposed to one or more chemicals or compounds to induce or repress signaling pathways (e.g., signal transduction pathway) or other cellular function. However, it should be understood that these cells and exemplary methods might be used for imaging and distinguishing other moving objects that have identifiable photometric and morphometric features, such as systems biology structures (cytomic objects), organelles, liposomes, subcellular compartments, polymeric microspheres or capsules, nanostructures, nanomolecules, and the like.


In the embodiments of the present invention, it is to be understood that relative movement exists between the object being imaged and the imaging system. In most cases, it will be more convenient to move the object than to move the imaging system. However, it is also contemplated that in some cases, the object may remain stationary and the imaging system move relative to it. As a further alternative, both the imaging system and the object may be in motion, which movement may be in different directions and/or at different rates.


In any of the aforementioned methods, multiple images may be collected simultaneously. Furthermore, in any of the aforementioned methods, there is relative motion between the cell and the detector. In addition, in any of the aforementioned methods, the detector is a time delay integration charge-coupled detector.


Compartmental Correlation Feature


As set forth above, the methods of the instant disclosure have been designed to overcome the shortcomings of the Nuc-Cyt difference calculation when monitoring, for example, nuclear translocation. That is, the Nuc-Cyt calculation requires, among other routines, accurate determination of a nuclear mask, subjective erosion and dilation routines that determine the nuclear and cytoplasmic boundaries, and subjective dilation of the cytoplasm mask to create an annular volume. The instant disclosure provides the use of an imaging system to track or correlate the movement of a molecule in a cell using a calculation referred to as Compartmental Correlation Feature (CCF). For example, using the multispectral imaging capabilities of an imaging system (e.g., ImageStream®), at least two different spectral images are collected corresponding to the emission wavelengths of a fluorescent dye specific for a cellular compartment (e.g., nucleus, mitochondria, cytoplasm, membrane) and a fluorescent dye specific for a translocated molecule. A cellular compartment mask may be generated based on the cellular compartment stain image, then a correlation measurement is made between the cellular compartment mask and the dye area of the translocated molecule. Consequently, molecules that are translocated to the targeted cellular compartment should have a high correlation (i.e., the images should show significant overlap), whereas cells lacking cellular compartment translocation should have a low correlation (i.e., images that show less of an overlap). The correlation value for each cell can be plotted as a histogram, which will display the degree of cellular compartment translocation of a molecule for a cell population. Furthermore, as noted above, the CCF can be used to determine or analyze molecular movement within any cellular compartment, such as translocation to or from the nucleus, movement to or from the cytoplasm, or movement to or from a cellular membrane, etc., and combinations thereof.



FIG. 2 illustrates the case of a nuclear translocation assay in which a fluorescent nucleic acid binding dye, 7-aminoactinomycin D (7-AAD, shown as red fluorescence), is used to stain the nucleus, while a different fluorescent marker (green; e.g., a FITC conjugated antibody) is used to label a translocating molecule of interest (e.g., NF-κB). Using the multispectral imaging capabilities of, for example, the ImageStream®, at least two different spectral images are collected, corresponding to the emission wavelengths of the nuclear fluorescent dye and the fluorescent dye on the molecule NF-κB (to track translocation). A nuclear mask is generated from the nuclear stain image and then a correlation measurement is made between the nuclear mask area of both fluorescence channels. Cells that exhibited nuclear translocation of NF-κB had a high correlation (see, e.g., FIG. 2C, image rows 2-4), while cells with low nuclear translocation had a low correlation (see, e.g., FIG. 2C, image row 1). The correlation value for each cell was plotted as a histogram, which displays the degree of NF-κB nuclear translocation for the cell population (see, e.g., FIG. 2C, graph on right).


Compartmental Correlation Feature Calculation


Compartmental Correlation is a measurement based upon a statistical definition of correlation. The correlation of X and Y is the measurement defined by

ρ(X,Y)=Cov(X,Y)/(σX σY)

in which X and Y are the fluorescent nuclear and translocating molecule. images.


Cov(X,Y) is the covariance of X and Y and is defined by:

    • Cov(X,Y)=Expected Value of [(X−μX) (Y−μY)]


      Also, μXX and μYY are the mean and standard deviations of X and Y, respectively. The measurement ρ(X,Y) is also known as the correlation coefficient. Correlation is most effective in measuring relationships between X and Y that are linear.


Similarity can be correlation, which is applied to imagery wherein X and Y are the pixel representations of imagery. First, the mask, M, is defined, wherein M is the set of coordinates (i,j). Then N can equal the number of elements in the set M. Then:

μX=ΣX(i,j)/N and σX=sqrt{Σ(X(i,j)−μX) (X(i,j)−μX))/(N−1)},
μY=ΣY(i,j)/N and σX=sqrt{Σ(Y(i,j)−μY) (Y(i,j)−μY))/(N−1)},
Cov(X,Y)=Σ(X(i,j)−μX) (Y(i,j)−μY))/(N−1)


When Compartmental Correlation is applied to images that exhibit molecular movement or translocation, this value tends to shift closer to a value of 1.0. When the images reveal lack of molecular movement or translocation (untranslocation), this value tends to shift closer to a value of −1.0. The Compartmental Correlation measurement and the imagery indicate that the different degree of translocation of NFκB into the nucleus is a linear relationship. Therefore, Compartmental Correlation is optimal for measuring such a relationship.


An exemplary embodiment of such a correlation is shown in FIG. 3. In order to quantitate the extent of NF-κB nuclear translocation in A-549 cells treated with TNF-α/IL-β, the degree of pixel intensity between the NF-κB and nuclear images of cell within a masked region of interest was analyzed. The NF-κB image of a cell with a high degree of translocation will look qualitatively similar to the nuclear image of that cell, resulting in a high degree of correlation between the two images. In contrast, the NF-κB image of a cell without any translocation will have little signal in the nuclear space, resulting in an inverse correlation with the nuclear image. FIG. 3A shows the masked areas used for the correlation analysis on an untranslocated and a translocated cell. Two features were calculated, the correlation coefficient (ρ) and, in this case, similarity is calculated as a logarithmic transformation of ρ, which features are represented by the following formula, respectively:

ρ(X,Y)=Cov(X,Y)/(σX σY)
Similarity=ln(1+ρ)/(1−ρ)

As set forth herein, ρ measures the degree to which the spatial distribution of intensities over two separate images is correlated, with a range from −1 (inverse correlation) to +1 (complete correlation). Here, similarity values range from −∞ to +∞, allowing standard statistical comparisons (means and standard deviations) between groups to be made. Histogram overlays of NF-κB/7-AAD correlation and similarity allows the differentiation of untreated (green) A-549 cells from TNF-α/IL-1β treated (red) A-549 cells. As described herein, the fidelity of these classifiers can be validated by inspection of the image galleries of the cells.


Mask Determination


In order for the correlation between pixel intensities to provide unambiguous evidence for or against the co-location of probes (e.g., labeled molecules) in cells, an appropriate sub-set of pixels should be selected over which the correlation is to be computed. If, for example, background pixels not belonging to the cell of interest are included in the set, a strong positive correlation may be found, even when the probes tend to separate within the cell because both probes are present in larger quantities within the cell than outside the cell. In general, a variety of chemical, morphological, and intensity-based methods may need to be applied in a given experiment to select the pixels of interest.


In the example of nuclear translocation, the task of selecting the pixels of interest is simplified by the presence of the nuclear probe. In this assay, the pixels of interest are those directly illuminated by the nucleus and cytoplasm. The presence of the nuclear probe means that all that is usually needed to get a sufficiently accurate set of pixels is a mask based on a blurred image of the nuclear probe, perhaps extended to include regions (near the nucleus) where the nuclear probe intensity is varying sufficiently rapidly. In the case of membrane probes, certain parameters should be chosen, such as a narrow band of pixels right on the edge of the cell, while excluding from consideration those either on the interior or exterior. Morphological criteria will play a role in constructing an appropriate set of pixels in the case of membranes and the morphology required is of two types. The first is a local constraint, requiring the band of pixels of increased intensity to be sufficiently narrow in order to qualify as a piece of the membrane. The second is a more global criterion, requiring that the band of pixels be sufficiently close to the global boundary defining the interior of the cell.


Uses


A multispectral imaging system and CCF can be used in a variety of applications, including diagnostics, drug discovery, and the like. For example, an imaging system may be used to identify compounds that affect or alter the activation of transcription factor NF-κB in cells of the immune system. Immune cells may be contacted with particular chemicals, cytokines, or environmental agents to examine whether translocation of the NF-κB molecule from the cytoplasm to the nucleus occurs as part of an immune response. The quantitative measurement of the amount of NF-κB in the nucleus versus the cytoplasm may, therefore, be extremely useful in the development of drugs that target immune function. Conventional high content screening systems are hindered in the analysis of NF-κB distribution due to the difficulty of imaging non-adherent immune cells on slides or plates and accurately measuring the quantity of NF-κB in the thin band of cytoplasm that characterize immune cells. The ImageStream platform, for example, eliminates these constraints with its ability to image non-adherent cells directly in suspension, its high resolution, and the statistical power (e.g., use of CCF) associated with its ability to analyze tens of thousands of cells.


By way of background, it is well established that Tumor Necrosis Factor-α (TNF-α) and Interleukin 1-β (IL-1β) induce translocation of NPκB from the cytoplasm to the nucleus in many cell types. In FIG. 11, an adherent human lung carcinoma cell line A-549 was either not treated or treated for 1 hr with IL-1β and TNF-α. The cells were trypsinized and washed off the plate to adapt the cells to flow, and probed for NF-κB (stained with anti-NF-κB mAb—AF 488donkey anti-mouse IgG). The nucleus was also stained with 7-AAD. Using ImageStream and the CCF, a quantifiable difference in the nuclear localization NF-κB was observed when comparing untreated and IL-1β/TNF-α treated cells (see FIGS. 11 and 13). Thus, the methods of the present disclosure may be used with adherent cells and cell lines.


By way of background and wishing to be bound by theory, NF-κB resides predominantly in the cytoplasm in resting cells. Activating treatments (e.g., IL-1β/TNF-α or LPS) induce NF-κB translocation into the nucleus in responsive cell types. Thus, the ratio of nuclear to cytoplasmic NF-κB increases with LPS treatment. Similar to the A-549 cells, NF-κB is translocated from the cytoplasm to the nucleus when the non-adherent human monocyte cell line, THP-1, is exposed to lipopolysaccharide (LPS). Using the identical probing protocol and CCF, again a quantifiable difference in the nuclear localization NF-κB is demonstrated when comparing untreated and LPS-treated cells (see FIGS. 6 and 9). A nuclear and NF-κB pixel signal correlation analysis CCF was used to quantitate the difference between untranslocated NF-κB and NF-κB translocated to the cell nucleus. The CCF distinguished location-specific (nuclear and cytoplasmic) quantitation of NF-κB to distinguish LPS-treated from untreated THP-1 cells. Thus, the methods of the present disclosure may also be used with non-adherent cells and cell lines.


Classifier Approach: Compartmental Correlation Feature Scoring


The CCF is an algorithmic feature that correlates the variation of pixels (from the mean) across two channels, in this case the 7-AAD (nuclear) and NF-κB channels, within a generous 75% 7-AAD mask. This feature reduces cell-to-cell variation judgment calls associated with integrated nuclear to cytoplasmic NF-κB intensity ratios. This feature also avoids cell-to-cell variation in the inclusion/expulsion of background-like pixels associated with user defined NK-κB masks (see FIGS. 9 and 13).


All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety. The invention having been described, the following examples are intended to illustrate, and not limit, the invention.


EXAMPLES
Example 1
Induction of Translocation in Adherent Cells

Human lung carcinoma cell line A-549, obtained from ATCC (Rockville, Md.), was maintained in RPMI 1640 (Gibco, Grand Island, N.Y.) containing 5% fetal bovine serum, 1 mM sodium pyruvate (Mediatech, Herndon, Va.), 100 μM nonessential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (Bio Whittaker, Walkersville, Md.) in 5% CO2 atmosphere at 37° C. The density of exponentially growing cells was less than 3×105 cells per ml at the time of all treatments. To induce NF-κB translocation into the nucleus from the cytoplasm, cells were treated for 1 hr with IL-1β and TNF-α.


The following is the experimental procedure for TNF-α/IL-1β induced Nuclear Translocation of NF-κB in A-549 cells


Samples:


1) Unstained and single fluorescent color control samples—start with 3.0×106 total cells each. In this experiment, controls are: unstained






    • NFκB Alexa F1uor 488

    • 7-AAD


      At the end, resuspend in 100 μl 0.1% triton X-100/PBS.





Unstained and NFκB can be mixed and run as one file, then a separate .rif of unlabeled cells can be created in IDEAS. The 7-AAD control must be run separately, because 7-AAD comes off of labeled cells and stains unlabeled cells, confounding compensation. Furthermore, we run the sample with 7-AAD in the buffer to increase staining intensity (washing it away reduces the intensity about four-fold)


2) Experimental samples—start with 8×106 total cells for untreated and 107 for TNF/IL-1 treated. Stain according to following protocol.


A-549 cells require special handling to resuspend properly. Resuspend pellets by pipeting up and down with a pipetman until cells appear dispersed. Then vortex.


A. Materials


01. anti-NFκB (F6): Santa Cruz Biotechnology (Cat. No. SC-8008), 200 μg/ml


02. Alexa Fluor 488 donkey anti-mouse IgG: Molecular Probes 1.1 mg/ml


03. Streptavidin Alexa Fluor 488: Molecular Probes


04. Recombinant human TNF-α: BD (Cat# 554618, Lot# 0000056653)


05. Recombinant human IL-1□: eBioscience (Cat# 14-8018-62)


06. A549 cells (ATCC No. CCL-185)


07. Dulbecco's MEM


08. Fetal Calf Serum


09. F-25 Culture Flask


10. 0.25% trypsin/EDTA


11. Phosphate buffered saline without Ca2+/Mg2+ (PBS)


12. 4% PFA/PBS (Fixation Buffer)


13. 0.1% triton X-100/PBS (Perm Buffer)


B. Cell Preparation


We used A549 cells cultured in Dulbecco's MEM supplemented with 10% fetal calf serum in an incubator containing 5% CO2 at 37. A-549 cells were stimulated with or without TNF-α and IL-1β for 45 min to induce nuclear translocation of NF-κB.


01. Culture A549 cells in the T-75 cm2 culture flask containing 20 ml of the 10% FCS/Dulbecco's MEM.


02. Stimulate the exponentially growing cells with TNF-α (2.0 ng/ml) and IL-1β (10 pg/ml) for 45 min at 37° C. under 5% CO2 humidified atmosphere.


03. After stimulation, discard media and wash cells with 5-10 ml of PBS.


04. Add 2 ml of 0.25% trypsin/EDTA to cells, and incubate 37° C. for 1 min or until cells have detached.


05. Suspend cells by adding 8 ml of complete DMEM.


06. Transfer the cell suspension to 15 ml centrifuge tube.


07. Centrifuge at 300× g 10′, 4° C., and remove media.


08. Fix cells by resuspending at 107 cells/ml in 4% PFA/PBS 30′, 4° C.


09. Wash with PBS, then perm cells by resuspending at 2×107 cells/ml in 0.1% triton X-100/0.02% EDTA/PBS (Perm) 30′, 4° C.


10. Add equal volume of anti-NFκB 20 μg/mL in Perm (final mAb concentration of 10 μg/mL) 15′, 4° C.


11. Wash Perm Buffer.


12. Resuspend 107 cells/ml in Perm+AF 488 donkey anti-mouse IgG (10 μg/mL) 15′, 4° C.


13. Filter 70 μm mesh and wash with Perm.


14. Resuspend 5×107 cells/ml Perm+10 μM 7-AAD 5′ and run directly on the ImageStream.


Example 2
Induction of Translocation in Non-Adherent Cells

Human monocyte cell line THP-1, obtained from ATCC (Rockville, Md.), were maintained in RPMI 1640 (Gibco, Grand Island, N.Y.) containing 5% fetal bovine serum, 1 mM sodium pyruvate (Mediatech, Herndon, Va.), 100 μM nonessential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (BioWhittaker, Walkersville, Md.) in 5% CO2 atmosphere at 37° C. The density of exponentially growing cells was less than 3×105 cells per ml at the time of all treatments. To induce NF-κB translocation into the nucleus from the cytoplasm, cells were treated for 1 hr with LPS.


The following is the experimental procedure for LPS-induced Nuclear Translocation of NF-κB in THP-1 cells.


Samples:


1) Unstained and single fluorescent color control samples—start with 3.0×106 total cells each. In this experiment, controls are:

    • unstained
    • NFκB Alexa Fluor488
    • 7-AAD


      At the end, resuspend in 100 μl 0.1% triton X-100/PBS.


Unstained and NFκB can be mixed and run as one file, then a separate .rif of unlabeled cells can be created in IDEAS. The 7-AAD control must be run separately, because 7-AAD comes off of labeled cells and stains unlabeled cells, confounding compensation. Furthermore, we run the sample with 7-AAD in the buffer to increase staining intensity (washing it away reduces the intensity about four-fold).


2) Experimental samples—start with 107 total cells for untreated LPS-treated. Stain according to following protocol.


A. Materials


1. anti-NFκB (F6): Santa Cruz Biotechnology (Cat. No. SC-8008), 200 μg/ml


2. Alexa Fluor 488 donkey anti-mouse IgG: Molecular Probes, 1.1 mg/ml


3. Streptavidin Alexa Fluor 488: Molecular Probes


4. Lipopolysaccharide (LPS) from E. Coli 0111 B4: Sigma (Cat# L2630)


5. THP-1 cells


6. RPMI


7. Fetal Calf Serum


8. T-75 cm2 Culture Flask


9. EDTA


10. Phosphate buffered saline without Ca2+/Mg2+ (PBS)


11. 4% PFA/PBS (Fixation Buffer)


12. 0.1% triton X-100/PBS (Perm Buffer)


B. Cell Preparation


We used THP-1 cells cultured in RPMI supplemented with 10% fetal calf serum in an incubator containing 5% CO2 at 37. THP-1 cells were stimulated with or without LPS and for 60 min to induce nuclear translocation of NF-κB.


1. Culture THP-1 cells in the T-75 cm2 culture flask containing 50 ml of the 10% FCS/RPMI (3×105 cells/mL).


2. Stimulate the exponentially growing cells with LPS for 60 min at 37° C. under 5% CO2 humidified atmosphere.


3. Centrifuge at 300× g 10′, 4° C., and remove media.


4. Fix cells by resuspending at 107 cells/ml in 4% PFA/PBS 30′, 4° C.


5. Wash with PBS, then perm cells by resuspending at 2×107 cells/ml in 0.1% triton X-100/0.02% EDTA/PBS (Perm) 30′, 4° C.


6. Add equal volume of anti-NFκB 20 μg/mL in Perm (final mAb concentration of 10 μg/mL) 15′, 4° C.


7. Wash Perm Buffer.


8. Resuspend 107 cells/ml in Perm+AF 488 donkey anti-mouse IgG (10 μg/mL) 15′, 4° C.


9. Filter 70 μm mesh and wash with Perm.


10. Resuspend 5×107 cells/ml Perm+10 μM 7-AAD 5′ and run directly on ImageStream.


Example 3
Nuclear Staining and NF-κB Staining

Control (untreated) cell and LPS or IL-1β/TNF-α treated cells were independently counted and washed once in phosphate buffered saline (PBS, Fair Lawn, N.J.). Each cell group was resuspended at 107 cells/ml in 10 μM 7-aminoactinomycin D (7-AAD, Molecular Probes) for 10 minutes at room temperature. Cells were additionally stained with anti-NF-κB mAb—AF 488 donkey anti-mouse IgG. Each cell group was washed, fixed in 2% paraformaldehyde (Sigma), and analyzed by flow cytometry and immunofluorescence microscopy.


Example 4
Conventional Flow Cytometry and Imaging Flow Cytometry

For flow cytometry, cell fluorescence data excited by a 488 nm laser were acquired using the FACSort™ cytometer (BD Immunocytometry Systems, San Jose, Calif.) and analyzed using CellQuest™ (BD Immunocytometry Systems). For imaging flow cytometry, fixed cells at 5×107 cells per ml were run at 100 cells per second on an ImageStream100™ (“Beta” version), and the data analyzed using the ImageStream Data Analysis and Exploration Software™ (IDEAS™).


Example 5
Instrumentation for Multispectral Imaging Flow Cytometry

Figures in U.S. Patent Application No. 2002/0146734 provide an exemplary layout of the ImageStream™ platform. Cells are hydrodynamically focused into a core stream and orthogonally illuminated for both darkfield and fluorescence imaging. The cells are simultaneously trans-illuminated via a spectrally-limited source (e.g., filtered white light or a light emitting diode) for brightfield imaging. Light is collected from the cells with an imaging objective lens and is projected on a charge-coupled detector (CCD). The optical system has a numeric aperture of 0.75 and the CCD pixel size in object space is 0.5 microns square, allowing high resolution imaging at event rates of approximately 100 cells per second. Each pixel is digitized with 10 bits of intensity resolution, providing a minimum dynamic range of three decades per pixel. In practice, the spread of signals over multiple pixels results in an effective dynamic range that typically exceeds four decades per image. Additionally, the sensitivity of the CCD can be independently controlled for each multispectral image, resulting in a total of approximately six decades of dynamic range across all the images associated with an object.


Prior to projection on the CCD, the light is passed through a spectral decomposition optical system that directs different spectral bands to different lateral positions across the detector (see, e.g., U.S. Pat. No. 6,249,341). With this technique, an image is optically decomposed into a set of 6 sub-images, each corresponding to a different color component and spatially isolated from the remaining sub-images. This is exemplified in U.S. Patent Application No. 2002/0146734, which depicts a red brightfield illumination source and the associated transmitted light images in the red detector channel adjacent to fluorescent and scattered light images in the other spectral channels. The process of spectral decomposition occurs during the image formation process rather than via digital image processing of a conventional composite image.


The CCD is operated using time-delay-integration (TDI), in which image photons converted to photocharges in an array of pixels are continuously shifted (at a rate synchronized with the velocity of the flowing cell's image) from pixel to pixel down the detector and parallel to the axis of flow to avoid image streaking. For example, the instrument can operate at a continuous data rate of approximately 30 megapixels per second and integrate signal from each object for 10 milliseconds, which allows the detection of even faint fluorescent probes within cell images that are acquired at high speed. Attention to pump and fluidic system design to achieve highly laminar, non-pulsatile flow can eliminate cell rotation or lateral translation on the time scale of the imaging process (see, e.g., U.S. Pat. No. 6,532,061). Every pixel read from the CCD is analyzed by a real-time algorithm that detects the presence of object images and calculates a number of basic morphometric and photometric features, which can be used as criteria for data storage. Data files encompassing 10,000-20,000 cells can be about 100 MB in size, and are stored and analyzed using standard personal computers.


Example 6
Immunofluorescence Microscopy

Fixed control and treated cells were placed on a conventional glass slide (Erie Scientific, Portsmouth, N.H.), mixed 1:1 with Antifade (Molecular Probes) and covered with a cover slip. The cells were visualized at 400X using an Eclipse E600 (Nikon, Melville, N.Y.) fluorescence microscope equipped with filters appropriate for Alexa Fluor 488 (535/40 nm emission) and 7-AAD (630/60 nm emission).


From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims
  • 1. A method for measuring molecular movement in a cell, comprising: contacting a cell with a compartment marker and with a molecular marker; imaging the marked cell with a detector;creating a compartment mask; andcorrelating said compartment mask and said molecular marker to measure molecular movement in a cell.
  • 2. The method of claim 1 wherein there is relative motion between the cell and the detector.
  • 3. The method of claim 1 wherein the molecular marker is a fluorescent labeled antibody.
  • 4. The method of claim 1 wherein the compartment marker is a fluorescent molecule.
  • 5. The method of claim 1 wherein the compartment marker is a nucleus, cytoplasm, or a membrane.
  • 6. The method of claim 1 wherein the molecule marked is NF-κB.
  • 7. The method of claim 1 further comprising the step of inducing molecular movement in the cell.
  • 8. The method of claim 7 wherein the induced molecular movement is nuclear translocation.
  • 9. The method of claim 7 wherein the molecular movement is induced with LPS or IL-1β/TNF-α.
  • 10. A method for measuring nuclear translocation in a cell, comprising: contacting a cell with a nuclear marker and with a molecular marker;imaging the marked cell with a detector, creating a nuclear mask; andcorrelating said nuclear mask and said molecular marker to measure molecular movement in a cell.
  • 11. The method of claim 10 wherein there is relative motion between the cell and the detector.
  • 12. The method of claim 10 further comprising the step of inducing molecular movement in the cell.
  • 13. The method of claim 12 wherein the induced molecular movement is nuclear translocation.
  • 14. The method of claim 12 wherein the molecular movement is induced with LPS or IL-1β/TNF-α.
  • 15. The method of claim 10 wherein the nuclear marker is 7-AAD.
  • 16. The method of claim 10 wherein the molecule marked is NF-κB.
  • 17. The method according to any one of claims 1-16 wherein the images are collected simultaneously.
  • 18. The method according to any one of claims 1-16 wherein the detector is a time delay integration charge-coupled detector.
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2005/008866 3/16/2005 WO 00 10/22/2008
Publishing Document Publishing Date Country Kind
WO2005/098430 10/20/2005 WO A
US Referenced Citations (154)
Number Name Date Kind
3497690 Gunter et al. Feb 1970 A
3555280 Richards, Jr. Jan 1971 A
3586760 Dillenburger Jun 1971 A
3922069 Kishikawa et al. Nov 1975 A
4313734 Leuvering Feb 1982 A
4414575 Yamamoto et al. Nov 1983 A
4635293 Watanabe Jan 1987 A
4662742 Chupp May 1987 A
4677680 Harima et al. Jun 1987 A
4703017 Campbell et al. Oct 1987 A
4737932 Baba Apr 1988 A
4770992 Van den Engh et al. Sep 1988 A
4777525 Preston, Jr. Oct 1988 A
4786165 Yamamoto et al. Nov 1988 A
4845197 Petersen et al. Jul 1989 A
4857453 Ullman et al. Aug 1989 A
4959302 Cornaby et al. Sep 1990 A
5096807 Leaback Mar 1992 A
5107522 Kitayama et al. Apr 1992 A
5122453 Martin et al. Jun 1992 A
5141609 Sweedler et al. Aug 1992 A
5153916 Inagaki et al. Oct 1992 A
5159397 Kosaka et al. Oct 1992 A
5159398 Maekawa et al. Oct 1992 A
5159642 Kosaka Oct 1992 A
5247339 Ogino Sep 1993 A
5247340 Ogino Sep 1993 A
5257182 Luck et al. Oct 1993 A
5272354 Kosaka Dec 1993 A
5351311 Rogers et al. Sep 1994 A
5372936 Fraatz et al. Dec 1994 A
5422712 Ogino Jun 1995 A
5436144 Stewart et al. Jul 1995 A
5444527 Kosaka Aug 1995 A
5459240 Foxwell et al. Oct 1995 A
5471294 Ogino Nov 1995 A
5547849 Baer et al. Aug 1996 A
5548349 Mizuguchi et al. Aug 1996 A
5548395 Kosaka Aug 1996 A
5568315 Shuman Oct 1996 A
5596401 Kusuzawa Jan 1997 A
5621460 Hatlestad et al. Apr 1997 A
5625048 Tsien et al. Apr 1997 A
5633503 Kosaka May 1997 A
5644388 Maekawa et al. Jul 1997 A
5674743 Ulmer Oct 1997 A
5686960 Sussman et al. Nov 1997 A
5695934 Brenner Dec 1997 A
5733721 Hemstreet, III et al. Mar 1998 A
5754291 Kain May 1998 A
5760899 Eismann Jun 1998 A
5764792 Kennealy Jun 1998 A
5784162 Cabib et al. Jul 1998 A
RE35868 Kosaka Aug 1998 E
5828776 Lee et al. Oct 1998 A
5831723 Kubota et al. Nov 1998 A
5844670 Morita et al. Dec 1998 A
5848123 Strommer Dec 1998 A
5855753 Trau et al. Jan 1999 A
5900942 Spiering May 1999 A
5926283 Hopkins Jul 1999 A
5929986 Slater et al. Jul 1999 A
5939281 Lehmann et al. Aug 1999 A
5959953 Alon Sep 1999 A
5965366 Ochoa et al. Oct 1999 A
5985549 Singer et al. Nov 1999 A
5986061 Pestka Nov 1999 A
6007994 Ward et al. Dec 1999 A
6007996 McNamara et al. Dec 1999 A
6014468 McCarthy et al. Jan 2000 A
6066459 Garini et al. May 2000 A
6108082 Pettipiece et al. Aug 2000 A
6115119 Sieracki et al. Sep 2000 A
6116739 Ishihara et al. Sep 2000 A
6150121 Hamawy et al. Nov 2000 A
6156465 Cao et al. Dec 2000 A
6159686 Kardos et al. Dec 2000 A
6210973 Pettit Apr 2001 B1
6211955 Basiji et al. Apr 2001 B1
6229913 Nayar et al. May 2001 B1
6249314 Yamamoto et al. Jun 2001 B1
6249341 Basiji et al. Jun 2001 B1
6256096 Johnson Jul 2001 B1
6259807 Ravkin Jul 2001 B1
6330081 Scholten Dec 2001 B1
6330361 Mitchell et al. Dec 2001 B1
6381363 Murching et al. Apr 2002 B1
6473176 Basiji et al. Oct 2002 B2
6507391 Riley et al. Jan 2003 B2
6510319 Baum et al. Jan 2003 B2
6519355 Nelson Feb 2003 B2
6522781 Norikane et al. Feb 2003 B1
6532061 Ortyn et al. Mar 2003 B2
6548259 Ward et al. Apr 2003 B2
6549664 Daiber et al. Apr 2003 B1
6563583 Ortyn et al. May 2003 B2
6580504 Basiji et al. Jun 2003 B1
6583865 Basiji et al. Jun 2003 B2
6608680 Basiji et al. Aug 2003 B2
6608682 Ortyn et al. Aug 2003 B2
6618140 Frost et al. Sep 2003 B2
6620591 Dunlay et al. Sep 2003 B1
6658143 Hansen et al. Dec 2003 B2
6671044 Ortyn et al. Dec 2003 B2
6671624 Dunlay et al. Dec 2003 B1
6707551 Ortyn et al. Mar 2004 B2
6716588 Sammak et al. Apr 2004 B2
6727066 Kaser Apr 2004 B2
6763149 Riley et al. Jul 2004 B2
6778263 Ortyn et al. Aug 2004 B2
6873733 Dowski, Jr. Mar 2005 B2
6875973 Ortyn et al. Apr 2005 B2
6906792 Ortyn et al. Jun 2005 B2
6927922 George et al. Aug 2005 B2
6934408 Frost et al. Aug 2005 B2
6947128 Basiji et al. Sep 2005 B2
6947136 Ortyn et al. Sep 2005 B2
6975400 Ortyn et al. Dec 2005 B2
7006710 Riley et al. Feb 2006 B2
7033819 Kim et al. Apr 2006 B2
7042639 McDowell May 2006 B1
7050620 Heckman May 2006 B2
7057732 Jorgenson et al. Jun 2006 B2
7079708 Riley et al. Jul 2006 B2
7087877 Ortyn et al. Aug 2006 B2
7139415 Finkbeiner Nov 2006 B2
7180673 Dowski, Jr. Feb 2007 B2
7190832 Frost et al. Mar 2007 B2
7221457 Jorgenson et al. May 2007 B2
7289205 Yaroslavsky et al. Oct 2007 B2
7306921 Nevalainen et al. Dec 2007 B2
7315357 Ortyn et al. Jan 2008 B2
7450229 Ortyn et al. Nov 2008 B2
7476514 Britz et al. Jan 2009 B2
7567695 Frost et al. Jul 2009 B2
7667761 Thomas Feb 2010 B2
20010006416 Johnson Jul 2001 A1
20010012620 Rich Aug 2001 A1
20020126275 Johnson Sep 2002 A1
20020146734 Ortyn et al. Oct 2002 A1
20030048931 Johnson et al. Mar 2003 A1
20030049701 Muraca Mar 2003 A1
20030059093 Rosania et al. Mar 2003 A1
20030104439 Finch Jun 2003 A1
20040093166 Kil May 2004 A1
20040111220 Ochs et al. Jun 2004 A1
20040241759 Tozer et al. Dec 2004 A1
20050014129 Cliffel et al. Jan 2005 A1
20060246481 Finch et al. Nov 2006 A1
20060257884 Brawley et al. Nov 2006 A1
20070054350 Walker, Jr. Mar 2007 A1
20070122806 Strom et al. May 2007 A1
20080240539 George et al. Oct 2008 A1
20090088409 Charlton Apr 2009 A1
Foreign Referenced Citations (27)
Number Date Country
0 154 404 Sep 1985 EP
0 280 559 Aug 1988 EP
0 281 327 Jun 1993 EP
0 372 707 Mar 1996 EP
0 950 890 Oct 1999 EP
1 316 793 Jun 2003 EP
WO 8808534 Nov 1988 WO
WO 9010715 Sep 1990 WO
WO 9520148 Jul 1995 WO
WO 9726333 Jul 1997 WO
WO 9853093 Nov 1998 WO
WO 9853300 Nov 1998 WO
WO 9924458 May 1999 WO
WO 9964592 Dec 1999 WO
WO 0006989 Feb 2000 WO
WO 0014545 Mar 2000 WO
WO 0042412 Jul 2000 WO
WO 0111341 Feb 2001 WO
WO 0146675 Jun 2001 WO
WO 0217622 Feb 2002 WO
WO 0218537 Mar 2002 WO
WO 0231182 Apr 2002 WO
WO 0235474 May 2002 WO
WO 02073200 Sep 2002 WO
WO 02079391 Oct 2002 WO
WO 2005090945 Sep 2005 WO
WO 2005098430 Oct 2005 WO
Related Publications (1)
Number Date Country
20090202130 A1 Aug 2009 US